Israel, we’re on our way! We leave Denmark with a smile and head down to sunny Tel-Aviv, where Compugen, a big Israeli-based leading drug discovery company and our Biotech of The Week, is located.
Employees: 93 (as of 03/2016)
Financial Data: €257.2M Market Cap (on 22/03/2016)
CEO: Anat Cohen-Dayan
Compugen-discovered drug targets are primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies, both as monotherapy and in combinations. Although headquartered in Israel, it also has R&D facilities at its South San Francisco wholly-owned subsidiary.
With a focus on Immuno-Oncology, CGEN-15029 is the lead internal program in the Company’s pipeline. It is in fact is one of the multiple novel immune checkpoint target candidates discovered by the Company through the use of its unique in silico predictive discovery platforms.